AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
PharmaNetics Engages Financial Advisor to Assist in Review of Strategic Alternatives.
Business Editors/Health/Medical Writers
RALEIGH, N.C.--(BUSINESS WIRE)--Jan. 16, 2004
PharmaNetics, Inc. (NASDAQ-SCM: PHAR), a leader in theranostic management specializing in managing the delivery of therapeutics affecting coagulation, today announced that the Company engaged Davenport & Company LLC ("Davenport"), an investment banking firm, as its financial advisor to assist the Company in pursuing a potential sale of its manufacturing operations and routine test business as well as review other strategic alternatives.
In connection with this development, John P. Funkhouser, president and chief executive officer, stated, "As previously announced, our goal is to evaluate strategic opportunities that will enable the Company to reduce overhead, preserve cash and keep its technology and manufacturing capability intact, while pursuing its claims against Aventis. In addition, the Company's Board of Directors intends to carefully evaluate any strategic opportunity that can maximize shareholder value."
PharmaNetics, Inc., a leading biotech company, conceived the term "theranostics," defining an emerging field of medicine that enables physicians to monitor the effect of antithrombotic agents in patients being treated for angina, myocardial infarction (heart attack), stroke, and pulmonary and arterial emboli. The Company develops, manufactures and markets rapid turnaround diagnostics to assess blood clot formation and dissolution. PharmaNetics develops tests based on its proprietary, dry chemistry Thrombolytic Assessment System. Its principal target market is the management of powerful new drug compounds, some of which may have narrow therapeutic ranges, ...
- PharmaNetics Receives $1.5 Million Payment From AstraZeneca.
- Press release article from: Business Wire July 26, 2001 700+ words
...trials. It is PharmaNetics' position that...desirable." PharmaNetics, Inc., a leading biotech company, conceived the...arterial emboli. PharmaNetics' proprietary...pharmaceutical companies, including Aventis...
- Court Confirms PharmaNetics' Allegation That Aventis Has Engaged in False...
- Press release article from: Business Wire May 4, 2004 700+ words
...BUSINESS WIRE)--May 4, 2004 PharmaNetics, Inc. (NASDAQ-SmallCap...Carolina. In November 2003, PharmaNetics, Inc. filed a lawsuit in...of French pharmaceutical company, Aventis. The lawsuit alleges...of false advertising, the PharmaNetics complaint includes allegations...
- PharmaNetics Puts Raleigh, N.C.-Area Manufacturing Plant Up on Sale Block.
- Newspaper article from: Knight Ridder/Tribune Business News December 17, 2003 700+ words
...that the French company has discouraged...jointly by the two companies. Selling the...would also allow PharmaNetics to focus on...model of the company to be more like...crucial deal for PharmaNetics and was expected...help turn the company profitable next year. But the ...
- PharmaNetics Announces Collaborative Sales and Marketing Program with Aventis...
- Press release article from: Business Wire January 9, 2003 700+ words
...milestone for our company and allows PharmaNetics to leverage its...applicable to any company introducing anticoagulants...Funkhouser, PharmaNetics' president and...are realized. PharmaNetics, Inc., a leading biotech company, conceived the...
- For shareholders, the future of PharmaNetics rests on lawsuit against Aventis.
- News wire article from: News & Observer (Raleigh, NC) March 31, 2005 700+ words
...drawing investors to PharmaNetics, a Raleigh diagnostics company in a bitter legal...to -- because PharmaNetics has nothing left...is the value the company has lost since...measure the damage PharmaNetics claims Aventis...
- Bayer Invests $17.4 Million in PharmaNetics; Companies Will Develop Future Near...
- Press release article from: Business Wire April 24, 2001 700+ words
...Theranostic market with PharmaNetics." The estimated annual...Background Information PharmaNetics, Inc. is a leader...arterial emboli. The Company's proprietary diagnostic...and dissolution. The Company has collaborations...major pharmaceutical companies, including Aventis...
- Morrisville, N.C.-Based PharmaNetics to Exit Nasdaq for Small-Cap Market.
- News wire article from: News & Observer (Raleigh, NC) September 23, 2003 700+ words
...Morrisville diagnostics company visibility with...is the least of PharmaNetics' problems. PharmaNetics...the Enox test, PharmaNetics "will continue...conserve cash, the company cut 13 positions earlier this year. PharmaNetics acknowledged in...
- PharmaNetics Completes Development Milestone With Platelet Function Theranostic...
- Press release article from: Business Wire September 21, 2000 700+ words
...21, 2000 PharmaNetics, Inc...that the Company has completed...between the two companies calls for PharmaNetics to demonstrate...emboli. The Company is currently...pharmaceutical companies including...performance of PharmaNetics that involve...
- Looking after the ashes: PharmaNetics board to decide.
- News wire article from: News & Observer (Raleigh, NC) July 6, 2006 700+ words
...trading of the company's stock will...dissolving the company for a year. That...a legal claim. PharmaNetics sued Aventis in...an agreement the companies had by falsely...hurting sales of PharmaNetics' test. PharmaNetics...estimate by the company's expert as speculative...
- Duke Clinical Research Institute and PharmaNetics Sign Collaborative Agreement...
- Press release article from: Business Wire December 7, 1999 700+ words
...7, 1999-- PharmaNetics, Inc. (NASDAQ...the holding company of Cardiovascular...will refer the PharmaNetics technology to any pharmaceutical company initiating clinical...require monitoring. PharmaNetics will develop a...
Source: HighBeam Research, PharmaNetics Engages Financial Advisor to Assist in Review of...